More Botanix Pharmaceuticals Limited news
Botanix Pharmaceuticals LimitedASX: BOT

Appendix 4C - quarterly

Apr 24, 2018 at 12:11 AM EDT · Issued by Botanix Pharmaceuticals Limited

Filed with ASX · Apr 24, 2018 at 12:11 AM EDT

On 6ix: 6ix.com/news/appendix-4c-quarterly-193

Watch Botanix Pharmaceuticals' latest call↗Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call↗

Botanix Pharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Botanix Pharmaceuticals Limited on 6ix

Earlier from Botanix Pharmaceuticals

  • Enrolment of BTX 1204 Atopic Dermatitis Study CompletedApr 9, 2018
  • Completion of PlacementFeb 11, 2018
  • Significantly Oversubscribed A$15m PlacementFeb 4, 2018
  • Botanix Announces Successful Acne Study ResultsJan 28, 2018
  • Botanix Receives A$1.6m R&D Tax Incentive RefundJan 15, 2018

Later from Botanix Pharmaceuticals

  • FDA Green Light for BTX 1503 Phase 2 StudyMay 7, 2018
  • Presentation on Atopic Dermatitis MarketMay 22, 2018
  • Botanix Announces Successful Atopic Dermatitis Study ResultsJun 5, 2018
  • BTX 1204 Atopic Dermatitis Study Results PresentationJun 6, 2018
  • Australian Ethics approval for Acne StudyJun 12, 2018
All Botanix Pharmaceuticals news releases↗

Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.

Follow Botanix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer